OBJECTIVES: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable cancer patients to gain access to therapies that are not routinely available on the NHS. A national CDF cohort policy lists drugs to be funded for patients who meet the relevant clinical criteria. Individual Cancer Drug Fund requests (ICDFRs) can also be made for patients outside of routine cohort CDF criteria for rare diseases or, in cases where a decision has been made not to fund a cohort, for patients for whom clinical exceptionality from this cohort can be demonstrated. ICDFRs are screened to ensure that the request is appropriate and are then appraised by one of four regional CDF panels. This research aimed to evaluate whether access to oncologics through ICDFRs varies by region. METHODS: ICDFR outcomes data (April 2013–March 2014) was extracted from the NHS website and stratified by NHS estimates of the resident population by region. All statistical analyses were performed using a Chi-squared test. RESULTS: